VFA
LOGC

Valeo Financial Advisors’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Valeo Financial Advisors’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-500
Closed -$4K – 2028
2021
Q1 		$4K Buy
+500
New +$4.11K ﹤0.01% 1663

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Valeo Financial Advisors's LOGC Position: Q2 2021 in Review

Valeo Financial Advisors sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2021, closing a stake of 500 shares — an estimated $4K sold.

Valeo Financial Advisors first reported a position in LOGC in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 63 funds tracked by Wall St. Rank hold LOGC as of Q2 2021.

  • Valeo Financial Advisors reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Valeo Financial Advisors sold 500 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $4K.
  • Valeo Financial Advisors first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Valeo Financial Advisors's LogicBio Therapeutics, Inc. Common Stock position peaked at $4K in Q1 2021.
  • 63 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Valeo Financial Advisors's 13F filing for Q2 2021, filed 22 Jul 2021.